HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Risk Committee To Consider Whether Earlier Information Is Really Better

This article was originally published in The Tan Sheet

Executive Summary

FDA is scrutinizing how it can make timely releases of safety information without sacrificing completeness and accuracy

FDA is scrutinizing how it can make timely releases of safety information without sacrificing completeness and accuracy.

"The historical strategy of waiting to communicate until the end of a lengthy evaluation and negotiation process doesn't work," said Nancy Ostrove, senior advisor for risk communication in FDA's Office of Planning.

"We don't want it so late that too many people experience preventable adverse events that could have been avoided. But we don't want it so early that people stop using or decide not to use a beneficial product, especially when the initial signal turns out not to have been associated with the product," Ostrove said at a Dec. 6 meeting of the Food and Drug Law Institute.

At the meeting in Washington, Randall Lutter, FDA's deputy commissioner for policy and planning, said the agency has yet to systematically analyze how the public receives and interprets safety information.

That task will be the primary mission of the Risk Communication Advisory Committee, which is expected to convene for the first time early this year. The 15-member advisory committee is charged with improving both risk and benefit communication at the agency (1 (Also see "FDA Risk Communication Panel’s Charter Is Tweaked As Members Are Named" - Pink Sheet, 19 Nov, 2007.), p. 14).

Responding to criticism that it sits too long on safety data received from firms, FDA has begun distributing early communications about ongoing safety reviews with ample caveats and no specific recommendations.

The early updates are "something we feel is incumbent on us to share with the public because it helps preserve confidence and trust in our management," Lutter said. "The trust is endangered if there is any suggestion that we are not acting quickly."

"We've never ever looked in a systematic way at the effectiveness of these efforts. Confidence is the core of the effectiveness of communication, and we must preserve it," he added.

Whether firms should similarly disclose risk information as soon as they uncover it is a tougher question, Lutter said. "The short answer is, 'We'd sure like that they'd share it with us.'"

- Jessica Bylander ([email protected])

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel